Glenmark Life Sciences Q2 Results
- BSE: 543322
- NSE: GLS
- ISIN: INE03Q201024
- Sector: Biotechnology & Drugs
BSE
1,073
10.55 (0.99%)
10.55 (0.99%)Volume5.92 K
Updated: Thu 16 Jan, 2025 | 15:29:20
NSE
1,072.456.85 (0.64%)
6.85 (0.64%)Volume86.23 K
Updated: Thu 16 Jan, 2025 | 15:29:51
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Income₹506.88 Cr.(-14.86%)
- Operating Profit₹119.27 Cr.(-22.53%)
- Profit After Tax₹95.32 Cr.(-19.73%)
- Operating Margin23.53%(-9.01%)
Note: Comparison is on YoY basis
Quarterly - Glenmark Life Sciences Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 24 | Jun 24 | QoQ Comp | Sep 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Revenue | 506.88 | 588.62 | -13.89% | 595.36 | -14.86% |
| Selling/ General/ Admin Expenses Total | 62.44 | 56.84 | 9.84% | 66.71 | -6.41% |
| Depreciation/ Amortization | 15.09 | 14.39 | 4.91% | 13.13 | 14.96% |
| Other Operating Expenses Total | 84.89 | 84.50 | 0.46% | 88.48 | -4.07% |
| Total Operating Expense | 387.61 | 443.52 | -12.60% | 441.41 | -12.19% |
| Operating Income | 119.27 | 145.10 | -17.80% | 153.95 | -22.53% |
| Net Income Before Taxes | 127.46 | 150.24 | -15.16% | 158.93 | -19.80% |
| Net Income | 95.32 | 111.48 | -14.50% | 118.74 | -19.73% |
| Diluted Normalized EPS | 7.75 | 9.08 | -14.65% | 9.69 | -20.02% |